Phase II trials are a critical step in the development of new cancer therapies. These trials aim to provide preliminary data on the effectiveness of a new treatment, usually after its safety has been confirmed in Phase I trials. Phase II trials typically involve a larger group of patients than Phase I trials, often ranging from 25 to 100 participants. The primary goal is to assess whether the new treatment has a biological effect against the cancer.
